IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals

Clinical Microbiology and Infection

Volumn 21, Issue 3, 2015, Pages 289.e1-289.e4

  Machmach, K ^a   Abad Molina, C ^a   Romero Sanchez M C ^a   Dominguez Molina, B ^a   Moyano, M ^b   Rodriguez, M M ^a   Rafii El Idrissi Benhnia, M ^a,c   Jimenez Mejias, M E ^a   Vidal, F ^d   Munoz Fernandez M A ^e,f   Genebat, M ^a   Viciana, P ^a   Gonzalez Escribano M F ^a   Leal, M ^a   Ruiz Mateos, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Centro Regional de Transfusiones Sanguíneas Sevilla Huelva y Banco de Tejidos   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

AIDS; CD4; HIV infection; IFNL4; IL28B

Indexed keywords

INTERFERON; INTERFERON LAMBDA 4; UNCLASSIFIED DRUG; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD; ALLELE; GENE LINKAGE DISEQUILIBRIUM; GENETIC LINKAGE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNITY; IMMUNOLOGY; MIXED INFECTION; OUTCOME ASSESSMENT; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC LINKAGE; GENOTYPE; HIV INFECTIONS; HUMANS; IMMUNITY; INTERLEUKINS; LINKAGE DISEQUILIBRIUM; MALE; PATIENT OUTCOME ASSESSMENT; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SPAIN; VIRAL LOAD;

EID: 84933566012     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.10.012     Document Type: Article

References (12)

1. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
2. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
3. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
4. Rallon N.I., Soriano V., Naggie S., Restrepo C., Goldstein D., Vispo E., et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011, 25:1025-1033.
5. Machmach K., Abad-Molina C., Romero-Sanchez M.C., Abad M.A., Ferrando-Martínez S., Genebat M., et al. IL28B single-nucleotide polymorphism rs12979860 is associated with spontaneous HIV control in white subjects. JInfect Dis 2013, 207:651-655.
6. Sajadi M.M., Shakeri N., Talwani R., Howell C.D., Pakyz R., Redfield R.R., et al. IL28B genotype does not correlate with HIV control in African Americans. Clin Transl Sci 2011, 4:282-284.
7. Salgado M., Kirk G.D., Cox A., Rutebemberwa A., Higgins Y., Astemborski J., et al. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS 2011, 25:385-387.
8. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. Avariant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45:164-171.
9. Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. JExp Med 2013, 210:1109-1116.
10. Aka P., Kuniholm M.H., Pfeiffer R.M., Wang A.S., Tang W., Chen S., et al. Association of the IFNL4-δG allele with impaired spontaneous clearance of hepatitis C virus. JInfect Dis 2014, 209:350-354.
11. Kramer B., Nischalke H.D., Boesecke C., Ingiliz P., Voigt E., Mauss S., et al. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS 2013, 27:2817-2819.
12. Morrow M.P., Pankhong P., Laddy D.J., Schoenly K.A., Yan J., Cisper N., et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009, 113:5868-5877.